Chimeric antigen receptor T cell (CAR-T) therapy demonstrated remarkable success in long-
term remission of cancers and other autoimmune diseases. Currently, six products (Kymriah …

Chimeric antigen receptor (CAR) T cell therapy, in which a patient's own T lymphocytes are
engineered to recognize and kill cancer cells, has achieved remarkable success in some …

Monoclonal antibodies are among the most effective tools for detecting tumor-associated
antigens. The US Food and Drug Administration (FDA) has approved more than 36 …

Chimeric antigen receptor (CAR) T cell therapy targeting B cell maturation antigen (BCMA)
has been approved for treating multiple myeloma (MM). Some clinical studies reported …

The treatment of breast cancer (BC) remains a formidable challenge due to the emergence
of drug resistance, necessitating the exploration of innovative strategies. Chimeric antigen …

Severe dengue virus (DENV) infection results from viral replication and dysregulated host
immune response, which trigger massive cytokine production/cytokine storm. The result is …

Cellular immunotherapy, particularly CAR-T cells, has shown potential in the improvement of
outcomes in patients with refractory and recurrent malignancies of the blood. However …

Adoptive T cell therapy using second-generation anti-CD19 chimeric antigen receptor T
cells (anti-CD19-CAR2-T) induced complete remission in many heavily pretreated patients …

Chimeric Antigen Receptor (CAR) T-cell therapies have emerged as an effective and
potentially curative immunotherapy for patients with relapsed or refractory malignancies …

Cancer has become one of the common causes of mortality around the globe due to
mutations in the genome which allows rapid growth of cells uncontrollably without repairing …